Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (November 2024)

16 slides from Rockwell Medical's investor presentation, Nov 12, 2024

1. Slide 1: Investor Presentation

   (©) ROCKWELL MEDICAL Investor Presentation November 12, 2024 RMTI Nasdaq Listec

2. Slide 2: Forward-Looking Statements and Non-GAAP Measures

   Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute “forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell’s expectations regarding revenue, profitability, financial position, 2024, 2025

3. Slide 3: Rockwell Medical At A Glance

   Rockwell Medical At A Glance Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Business Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview Second largest supplier o

4. Slide 4: Executive Management Team

   Executive Management Team Mark Strobeck, Ph.D. President and CEO Aquilo “ASSERTIO= Tim T. Chole Jesse Neri SVP, Finance ARUVANT te Symphony Health Zy| a9 SVP, Chief Commercial Officer Baxter (- Cochlear ‘GAMBRO. Watson Pharmaceuticals: © 2024 Rockwell Medical, Inc. Megan Timmins EVP, Chief Legal Off

5. Slide 5: Corporate Strategy

   Corporate Strategy QO) Be a Leading Global Supplier of Hemodialysis Concentrates O) Provide Customers with the Highest Quality and Most Reliable Products and Services () Achieve $100M+ Annual Net Sales and Sustain Profitability QO) Focus on Innovative, Long-Term Growth Opportunities © 2024 Rodwell M

6. Slide 6: Only Two Major Manufacturers and Suppliers of Concentrates

   Only Two Major Manufacturers and Suppliers of Concentrates Approximately 475,000 patients in the U.S. require in-center hemodialysis annually”). ¢ a Hemodialysis is a Necessity for End Stage Renal Disease Patients * Each patient receives approximately 3 treatments per week, totaling ~150 in-clinic p

7. Slide 7: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM

   U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease 2024 2028 SOURCE: CAGR based on “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) fm RMT © 2024 Rockwel

8. Slide 8: Growth Opportunities and Potential Additional Revenue Streams

   Growth Opportunities and Potential Additional Revenue Streams Geographic Expansion Pa Market Consolidation 5° Increase market share throughout the U.S. Several small, regional hemodialysis and internationally. Rockwell continues to concentrates manufacturers. Opportunity secure commercial partnershi

9. Slide 9: Financials and Milestones

   © ROCKWELL MEDICAL Financials and Milestones

10. Slide 10: Continue to Improve Rockwell's Financial Health

    Continue to Improve Rockwell’s Financial Health Generated Highest Quarterly Revenue and Gross Profit to Date Three Months Ended Nine Months Ended September 30 September 30 ——— a Net Sales $ 28.3 $ 23.8 $ 76.8 $ 615 Gross Profit $ 6.2 $ 2.2 $ 39) > 5.8 Operating Income (Loss) $ 1.9 $ (1.7) > 11 S (6.

11. Slide 11: Achievements Reflect Strong Foundational Business

    Achievements Reflect Strong Foundational Business ($ in millions) $100 $95 $90 $85 $98 -$101 2024 (E) Gross Profit (Loss) ($ in millions) $15 2024 (E) © 2024 Rockwell Medical, Inc. Gross Margin 16% — 18% 15% 10% 10% 5% 0% 5% 2021 2022 2023 2024 (E) (E) = Estimated QROCKWELL MEDTCAT

12. Slide 12: Projects Profitability on an Adjusted EBITDA Basis for FY'24

    Projects Profitability on an Adjusted EBITDA Basis for FY’24 (Sin millions) $(28.4) 2021 2022 2023 $4.0- $5.0 2024 (E) © 2024 Rockwell Medical, Inc. (€) = Estimated QROCKWELL MEDICAL

13. Slide 13: 2024 Projected Milestones

    2024 Projected Milestones Achieve profitability for the full-year 2024 on an adjusted EBITDA basis. Continue to optimize our business through improved processes and expanded automated manufacturing capabilities. Enhance our distribution capabilities through the modernization of our infrastructure an

14. Slide 14: Why Invest in Rockwell Medical?

    HAPPY — 29 LISTING ANNIVERSpy jJROCKWELL MEDIca, RMTI NasdagqListed Nasdaq Why Invest in Rockwell Medical? O) Experienced Management Team O) Large and Growing Market Opportunity C) Revenue-Generating Business O Profitable, Strong Financials O) Attractive Valuation © 2024 Rockwell Medical, Inc. © ROC

15. Slide 15: Rockwell Medical

    () ROCKWELL MEDICAL www.rockwellmed.com IR@rockwellmed.com

16. Slide 16: Reconciliation to GAAP Financial Measures

    Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat

Rockwell Medical — Investor Presentation (November 2024) on 6ix